Answers are grounded in this paper and cite their sources.
Lichen planus is a rare and chronic inflammatory skin disorder that imposes a high psychosocial burden on affected patients. Currently, no FDA-approved treatments exist for lichen planus, and it remains to be a therapeutic challenge for health care practitioners, especially in patients who are uninterested in trying topical corticosteroids or systemic therapies. We describe the reduction of erythema and resolution of pruritus following treatment with a once-daily nonsteroidal topical, roflumilast cream 0.3%, in a patient with lichen planus who had previously failed topical and intramuscular corticosteroid treatment.
No takes yet. Share an insight, caveat, or question.
A. De Winter Baker (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: